Clinical trial
A Phase II Safety and Tolerability Study of Bevacizumab When Added to…
NCT00476827 · Duke University, Other · Terminated
Key facts
| NCT number | NCT00476827 |
|---|---|
| Title | A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain |
| Official title | A Phase II Safety and Tolerability Study of Avastin When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain |
| Lead sponsor | Duke University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Docetaxel, CPT-11, Paclitaxel, Vinorelbine Tartrate, Gemcitabine |
| Enrollment | 16 |
| Start date | May 1, 2007 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | May 22, 2007 |
| Last update posted | Jul 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: